Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Henry Schein, Inc.    HSIC

HENRY SCHEIN, INC.

(HSIC)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Drug firms offer to settle U.S. opioid suits with $50 billion package: sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/16/2019 | 11:04pm EST
The logo of Teva Pharmaceutical Industries is seen during a news conference in Tel Aviv

(Reuters) - Five drugmakers and distributors are offering $22 billion in cash as well as drugs and services they value at $28 billion to resolve lawsuits alleging the industry fuelled the U.S. opioid crisis, two sources familiar with the matter said on Wednesday.

The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse. Local governments seek funds to cover costs of services in their communities.

Distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson & Johnson would pay $4 billion in cash, two people familiar with the matter told Reuters.

Teva Pharmaceutical Industries Ltd has offered to give away medications it values at $15 billion as part of the deal and provide distribution services it values in the billions, one of the people said.

Both said that Teva's proposed agreement would run over 10 years and had a total estimated value of around $28 billion. However, it is not clear how the valuation was reached, and one source said some states are asking whether Teva should pay cash as well.

The negotiations are being led by the attorneys general for Texas, Tennessee, North Carolina and Pennsylvania, one person said.

Teva and the three distributors are all defendants in a landmark trial set to begin in federal court in Cleveland, Ohio, on Monday. U.S. District Judge Dan Polster, who has long pushed for a global settlement of the litigation, will preside over the trial.

The distributors, accused of failing to halt and report suspicious drug orders, are pushing for a settlement to be agreed to before the trial begins on Monday, one source said. The second source added that a sticking point was compensation for lawyers who typically are paid a percentage of settlements and represent many of the state and local plaintiffs.

The sources cautioned that there was no guarantee a deal would be struck. One source said lawyers for the thousands of cities and counties with cases pending in federal court have not yet agreed to back the proposal the states are negotiating.

In a joint statement late on Wednesday, the lead attorneys for the cities and counties pursuing federal lawsuits - Joe Rice, Paul Farrell and Paul Hanly - called media reports that they were tentatively supporting the settlement proposal "inaccurate."

"We await the fine print of the settlement framework so that we can work alongside the 2,600 communities we represent to determine the best path forward," they said.

Jury selection went ahead on Wednesday in anticipation of opening statements on Monday. Other defendants in the trial are Walgreens Boots Alliance Inc and Henry Schein Inc.

Opioid addiction claimed roughly 400,000 lives in the United States from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.

The companies did not respond to requests for comment on Wednesday. J&J had said on Tuesday it was open to a settlement.

(Reporting by Tamara Mathias in Bengaluru and Nate Raymond in Boston; Additional reporting by Ann Maria Shibu in Bengaluru; Editing by Cynthia Osterman and Muralikumar Anantharaman)

By Nate Raymond and Shanti S Nair

Stocks mentioned in the article
ChangeLast1st jan.
HENRY SCHEIN, INC. 0.12% 69.1 Delayed Quote.9.70%
JOHNSON & JOHNSON 0.08% 134.9 Delayed Quote.4.56%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 4.68% 3690 Delayed Quote.-39.61%
WALGREENS BOOTS ALLIANCE -0.98% 61.24 Delayed Quote.-9.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HENRY SCHEIN, INC.
11/05HENRY SCHEIN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
11/05HENRY SCHEIN : Vertical Market Data
PU
11/05HENRY SCHEIN : Reconciliation of GAAP and Non-GAAP Measures
PU
11/05HENRY SCHEIN : 3Q Earnings Snapshot
AQ
11/05HENRY SCHEIN INC : Results of Operations and Financial Condition, Financial Stat..
AQ
11/05HENRY SCHEIN : Reports Record Third Quarter 2019 Financial Results From Continui..
BU
11/05HENRY SCHEIN, INC. : 3rd quarter results
CO
10/31HENRY SCHEIN : Disaster Relief Hotline Is Open to Support Customers Affected by ..
BU
10/31HENRY SCHEIN, INC. : quaterly earnings release
10/31HENRY SCHEIN : Announces $400 Million Increase to Share Repurchase Plan
BU
More news
Financials (USD)
Sales 2019 9 962 M
EBIT 2019 724 M
Net income 2019 500 M
Debt 2019 1 003 M
Yield 2019 -
P/E ratio 2019 20,5x
P/E ratio 2020 18,6x
EV / Sales2019 1,11x
EV / Sales2020 1,06x
Capitalization 10 080 M
Chart HENRY SCHEIN, INC.
Duration : Period :
Henry Schein, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HENRY SCHEIN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 68,06  $
Last Close Price 68,69  $
Spread / Highest target 16,5%
Spread / Average Target -0,92%
Spread / Lowest Target -18,5%
EPS Revisions
Managers
NameTitle
Stanley M. Bergman Chairman & Chief Executive Officer
James P. Breslawski Vice Chairman & President
Steven Paladino Chief Financial Officer, Director & Executive VP
Christopher Pendergast Chief Technology Officer & Senior Vice President
Philip A. Laskaway Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HENRY SCHEIN, INC.9.70%10 080
AMPLIFON S.P.A.78.22%6 185
CANTEL MEDICAL CORP.-4.22%3 036
SHIP HEALTHCARE HOLDINGS, INC.22.73%2 073
PATTERSON COMPANIES-4.37%1 774
AS ONE CORPORATION20.16%1 527